Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ribociclib under the microscope: how does it perform in real life?

NCT ID NCT06148506

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 376 people with HR+HER2- advanced breast cancer who are taking ribociclib (Risarg) plus endocrine therapy or chemotherapy as part of their routine care in Russia. The goal is to see how long patients stay on treatment before stopping for any reason. Since this is an observational study, no new treatments are being tested—just real-world outcomes are being tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ribociclib (Risarg) combined with endocrine therapy or chemotherapy
What this could lead to
If successful, this study could show how well ribociclib works in everyday practice, potentially guiding better treatment choices for advanced breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients in Russia, which may limit how broadly the findings apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+, HER2-, ADVANCED BREAST CANCER

Contacts and locations

Locations

  • Novartis Investigative Site

    Kaluga, Russia, 248007, Russia

  • Novartis Investigative Site

    Barnaul, 656045, Russia

  • Novartis Investigative Site

    Chelyabinsk, 454087, Russia

  • Novartis Investigative Site

    Irkutsk, 664035, Russia

  • Novartis Investigative Site

    Izhevsk, 426009, Russia

  • Novartis Investigative Site

    Kemerovo, 650036, Russia

  • Novartis Investigative Site

    Krasnodar, 350040, Russia

  • Novartis Investigative Site

    Krasnoyarsk, 660022, Russia

  • Novartis Investigative Site

    Moscow, 115304, Russia

  • Novartis Investigative Site

    Moscow, 115522, Russia

  • Novartis Investigative Site

    Moscow, 143423, Russia

  • Novartis Investigative Site

    Nal'chik, 360051, Russia

  • Novartis Investigative Site

    Podolsk, 142110, Russia

  • Novartis Investigative Site

    Saransk, 430032, Russia

  • Novartis Investigative Site

    Tambov, 392000, Russia

  • Novartis Investigative Site

    Tver', 170008, Russia

  • Novartis Investigative Site

    Ufa, 450054, Russia

  • Novartis Investigative Site

    Vladikavkaz, 362002, Russia

  • Novartis Investigative Site

    Yaroslavl, 150054, Russia

  • Novartis Investigative Site

    Yekaterinburg, 620036, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.